Owing to the potential synergistic effects of the combined administration of myeloablative ASCT and adoptive T-cell immunotherapy [8], we conducted an open-label, single-center, single-arm pilot study to explore the safety and efficacy of ASCT in tandem with CAR30 T-cell infusion in r/r CD30+ lymphoma. Here, TNFRSF8 is linked to lymphoma.